Prestroke Antiplatelet Effect on Symptomatic Intracranial Hemorrhage and Functional Outcome in Intravenous Thrombolysis
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose About 30%-40% of stroke patients are taking antiplatelet at the time of their strokes, which might increase the risk of symptomatic intracranial hemorrhage (SICH) with intravenous tissue plasminogen activator (IV-TPA) therapy. We aimed to assess the effect of prestroke antiplatelet on the SICH risk and functional outcome in Koreans treated with IV-TPA. Methods From a prospective stroke registry, we identified patients treated with IV-TPA between October 2009 and November 2014. Prestroke antiplatelet use was defined as taking antiplatelet within 7 days before the stroke onset. The primary outcome was SICH. Secondary outcomes were discharge modified Rankin Scale (mRS) score and in-hospital mortality. Results Of 1,715 patients treated with IV-TPA, 441 (25.7%) were on prestroke antiplatelet. Prestroke antiplatelet users versus non-users were more likely to be older, to have multiple vascular risk factors. Prestroke antiplatelet use was associated with an increased risk of SICH (5.9% vs. 3.0%; adjusted odds ratio [OR] 1.79 [1.05-3.04]). However, at discharge, the two groups did not differ in mRS distribution (adjusted OR 0.90 [0.72-1.14]), mRS 0-1 outcome (34.2% vs. 33.7%; adjusted OR 1.27 [0.94-1.72), mRS 0-2 outcome (52.4% vs. 52.9%; adjusted OR 1.21 [0.90-1.63]), and in-hospital mortality (6.1% vs. 4.2%; adjusted OR 1.19 [0.71-2.01]). Conclusions Despite an increased risk of SICH, prestroke antiplatelet users compared to non-users had comparable functional outcomes and in-hospital mortality with IV-TPA therapy. Our results support the use of IV-TPA in eligible patients taking antiplatelet therapy before their stroke onset.
Abstract
Background and Purpose About 30%-40% of stroke patients are taking antiplatelet at the time of their strokes, which might increase the risk of symptomatic intracranial hemorrhage (SICH) with intravenous tissue plasminogen activator (IV-TPA) therapy. We aimed to assess the effect of prestroke antiplatelet on the SICH risk and functional outcome in Koreans treated with IV-TPA. Methods From a prospective stroke registry, we identified patients treated with IV-TPA between October 2009 and November 2014. Prestroke antiplatelet use was defined as taking antiplatelet within 7 days before the stroke onset. The primary outcome was SICH. Secondary outcomes were discharge modified Rankin Scale (mRS) score and in-hospital mortality. Results Of 1,715 patients treated with IV-TPA, 441 (25.7%) were on prestroke antiplatelet. Prestroke antiplatelet users versus non-users were more likely to be older, to have multiple vascular risk factors. Prestroke antiplatelet use was associated with an increased risk of SICH (5.9% vs. 3.0%; adjusted odds ratio [OR] 1.79 [1.05-3.04]). However, at discharge, the two groups did not differ in mRS distribution (adjusted OR 0.90 [0.72-1.14]), mRS 0-1 outcome (34.2% vs. 33.7%; adjusted OR 1.27 [0.94-1.72), mRS 0-2 outcome (52.4% vs. 52.9%; adjusted OR 1.21 [0.90-1.63]), and in-hospital mortality (6.1% vs. 4.2%; adjusted OR 1.19 [0.71-2.01]). Conclusions Despite an increased risk of SICH, prestroke antiplatelet users compared to non-users had comparable functional outcomes and in-hospital mortality with IV-TPA therapy. Our results support the use of IV-TPA in eligible patients taking antiplatelet therapy before their stroke onset.
참고문헌 (20)
- Pan X, "Prior antiplatelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke : a meta-analysis of cohort studies and randomized controlled trials", Int J Stroke, 10, pp.317~323 (2015)
- Diedler J, "Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset", Stroke, 41, pp.288~294 (2010)
- Mazya M, "Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase : safe Implementation of Treatments in Stroke(SITS)symptomatic intracerebral hemorrhage risk score", Stroke, 43, pp.1524~1531 (2012)
- Whiteley WN, "Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator : a systematic review and meta-analysis of 55 studies", Stroke, 43, pp.2904~2909 (2012)
- Whiteley WN, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome : an analysis of the third international stroke trial", Stroke, 45, pp.1000~1006 (2014)
- Xian Y, "Risks and benefits associated with prestroke antiplatelet therapy among patients with acute ischemic stroke treated with intravenous tissue plasminogen activator", JAMA Neurol, 73, pp.50~59 (2016)
- Bluhmki E, "Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial", Lancet Neurol, 8, pp.1095~1102 (2009)
- Cucchiara B, "Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke : pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment(SAINT)I and SAINT II Trials", Stroke, 40, pp.3067~3072 (2009)
- Ibrahim MM, "Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke?", Cerebrovasc Dis, 30, pp.508~513 (2010)
- Larrue V, "Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator : a secondary analysis of the European-Australasian Acute Stroke Study(ECASS II)", Stroke, 32, pp.438~441 (2001)
- Tanne D, "Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice : the Multicenter rt-PA Stroke Survey", Circulation, 105, pp.1679~1685 (2002)
- Mehta RH, "Race", Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy, 2014, pp.45, 2263~2269
- Pan Y, "Preexisting dual antiplatelet treatment increases the risk of post-thrombolysis intracranial hemorrhage in Chinese stroke patients", Neurol Res, 37, pp.64~68 (2015)
- Chao AC, "Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients : the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke(TTT-AIS)study", Stroke, 41, pp.885~890 (2010)
- 김범준, "Case Characteristics, Hyperacute Treatment, and Outcome Information from the Clinical Research Center for Stroke-Fifth Division Registry in South Korea", 대한뇌졸중학회지, 17(1), pp.38~53 (2015), 대한뇌졸중학회
- 조경희, "한국 뇌졸중 진료지침 급성기 치료 중 혈전용해술에 대한 내용의 부분개정", 대한뇌졸중학회지, 14(3), pp.95~105 (2012), 대한뇌졸중학회[DOI]
- Kim BJ, "Current status of acute stroke management in Korea: a report on a multicenter, comprehensive acute stroke registry", Int J Stroke, 9, pp.514~518 (2014)
- Ciolino JD, "Covariate imbalance and adjustment for logistic regression analysis of clinical trial data", J Biopharm Stat, 23, pp.1383~1402 (2013)
- Wahlgren N, "Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials : Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy(SITS-MOST)", Stroke, 39, pp.3316~3322 (2008)
- Hallevi H, "Antiplatelet therapy and the risk of intracranial hemorrhage after intravenous tissue plasminogen activator therapy for acute ischemic stroke", Arch Neurol, 65, pp.575~576 (2008)